Flex Pharma (NASDAQ: FLKS) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Flex Pharma to similar businesses based on the strength of its profitability, valuation, earnings, institutional ownership, analyst recommendations, dividends and risk.
Risk & Volatility
Flex Pharma has a beta of 3.54, meaning that its share price is 254% more volatile than the S&P 500. Comparatively, Flex Pharma’s rivals have a beta of 6.07, meaning that their average share price is 507% more volatile than the S&P 500.
This table compares Flex Pharma and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Flex Pharma||$1.01 million||-$39.49 million||-1.56|
|Flex Pharma Competitors||$284.49 million||$34.10 million||70.43|
Flex Pharma’s rivals have higher revenue and earnings than Flex Pharma. Flex Pharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current recommendations and price targets for Flex Pharma and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Flex Pharma Competitors||877||3242||11729||233||2.70|
Flex Pharma currently has a consensus price target of $11.00, indicating a potential upside of 248.10%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.20%. Given Flex Pharma’s stronger consensus rating and higher probable upside, equities analysts clearly believe Flex Pharma is more favorable than its rivals.
Institutional and Insider Ownership
27.3% of Flex Pharma shares are held by institutional investors. Comparatively, 50.1% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 45.4% of Flex Pharma shares are held by company insiders. Comparatively, 17.2% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Flex Pharma and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Flex Pharma Competitors||-5,311.40%||-218.25%||-39.46%|
Flex Pharma Company Profile
Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.
Receive News & Ratings for Flex Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma and related companies with MarketBeat.com's FREE daily email newsletter.